|本期目录/Table of Contents|

[1]于晓钧,孙欣.AECOPD患者细菌和病毒感染类型及其与复发风险的相关性[J].中华肺部疾病杂志,2021,(03):325-328.[doi:10.3877/cma.j.issn.1674-6902.2021.03.015]
点击复制

AECOPD患者细菌和病毒感染类型及其与复发风险的相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年03期
页码:
325-328
栏目:
临床研究
出版日期:
2021-06-20

文章信息/Info

Title:
-
作者:
于晓钧1; 孙欣2
543002 广西梧州市红十字会医院急诊科1、护理部2
Author(s):
-
关键词:
急性加重; 肺疾病; 慢性阻塞性;  细菌;  病毒;  感染;  复发风险
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2021.03.015
摘要:
目的 探讨慢性阻塞性肺疾病急性加重(AECOPD)患者细菌和病毒感染类型及其与复发风险的相关性。方法 选择2018年8月至2019年9月于我院就诊的72例AECOPD患者为对象,所有受试者入院后均接受常规AECOPD治疗及细菌、病毒感染类型检测。治疗出院后随访1年,根据患者是否复发分为复发组和未复发组,并采用Cox回归分析AECOPD患者细菌、病毒感染类型与复发风险的相关性。结果 72例AECOPD患者中有40.27(29/72)存在病毒感染,43.06%(31/72)的患者细菌感染。铜绿假单胞菌是最常见细菌感染类型25.81%(8/31),其次是鲍曼不动杆菌和肺炎克雷伯菌22.58%(7/31); 人鼻病毒是最常见的病毒感染类型48.28%(14/29)和间质肺病毒37.93%(11/29)。随访1年后72例AECOPD患者共失访8例,最终纳入64例AECOPD患者,其中39例患者出现复发为复发组,未复发的25例患者为未复发组。单因素分析显示两组患者卡他莫拉菌、肺炎链球菌、流感嗜血杆菌、甲型流感病毒、人间质肺病毒、人鼻病毒感染比例组间比较差异有统计学意义(P<0.05)。结论 铜绿假单胞菌、人鼻病毒是AECOPD患者最常见细菌和病毒感染类型,且人鼻病毒、肺炎链球菌、流感嗜血杆菌是AECOPD患者复发的风险因素。
Abstract:
-

参考文献/References:

1 Wang J, Chai J, Sun L, et al. The sputum microbiome associated with different sub-types of AECOPD in a Chinese cohort[J]. BMC Infect Dis, 2020, 20(1): 610.
2 Pei Z, Sun Y, Wang S, et al. Estimating mortality among in patients with acute exacerbation of chronic obstructive pulmonary disease using registry data[J]. NPJ Prim Care Respir Med, 2020, 30(1): 28.
3 Ernst P, Dahl M, Chateau D, et al. Canadian network for observational drug effect studies(CNODES)Investigators. Comparative effectiveness of fluoroquinolone antibiotic use in uncomplicated acute exacerbations of COPD: a multi-cohort study[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 2939-2946.
4 Ra SW, Kwon YS, Yoon SH, et al. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(4): 1424-1432.
5 Montón C, Prina E, Pomares X, et al. Nebulized colistin and continuous cyclic azithromycin in severe COPD patients with chronic bronchial infection due to Pseudomonas aeruginosa: a retrospective cohort study[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 2365-2373.
6 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志, 2017, 37(14): 1041-1057.
7 Sperrin M, Webb DJ, Patel P, et al. Chronic obstructive pulmonary disease exacerbation episodes derived from electronic health record data validated using clinical trial data[J]. Pharmacoepidemiol Drug Saf, 2019, 28(10): 1369-1376.
8 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
9 Spencer L. Pulmonary rehabilitation for patients with acute chronic obstructive pulmonary disease exacerbations: is the evidence strengthening? [J]. Curr Opin Pulm Med, 2018, 24(2): 147-151.
10 Wang H, Anthony D, Selemidis S, et al. Resolving viral-induced secondary bacterial infection in COPD: a concise review[J]. Front Immunol, 2018, 9(1): 2345.
11 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
12 Su YC, Jalalvand F, Thegerström J, et al. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable Haemophilus influenzae[J]. Front Immunol, 2018, 9(1): 2530.
13 Messous S, Elargoubi A, Pillet S, et al. Bacterial and viral infection in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease: implication for antimicrobial management and clinical outcome[J]. COPD, 2021, 18(1): 53-61.
14 Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis[J]. Eur Respir Rev, 2017, 26(143): 160073.
15 Stolz D, Papakonstantinou E, Grize L, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation[J]. Eur Respir J, 2019, 54(4): 1900407.
16 Yin T, Zhu Z, Mei Z, et al. Analysis of viral infection and biomarkers in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(3): 1228-1239.
17 Alotaibi NM, Chen V, Hollander Z, et al. Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14(1): 311-319.
18 Santoro A, Tomino C, Prinzi G, et al. Microbiome in chronic obstructive pulmonary disease: role of natural products against microbial pathogens[J]. Curr Med Chem, 2020, 27(18): 2931-2948.
19 Eklöf J, Sørensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22?053 patients[J]. Clin Microbiol Infect, 2020, 26(2): 227-234.
20 Mulpuru S, Li L, Ye L, et al. Serious outcomes surveillance(SOS)network of the Canadian immunization research network(CIRN). Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD[J]. Chest, 2019, 155(1): 69-78.
21 Menzel M, Ramu S, Calvén J, et al. Oxidative stress attenuates TLR3 responsiveness and impairs anti-viral mechanisms in bronchial rpithelial cells from COPD and asthma patients[J]. Front Immunol, 2019, 10(1): 2765.
22 Choi J, Oh JY, Lee YS, et al. Bacterial and viral identification rate in acute exacerbation of chronic obstructive pulmonary disease in Korea[J]. Yonsei Med J, 2019, 60(2): 216-222.
23 Choi J, Oh JY, Lee YS, et al. Pseudomonas aeruginosa infection increases the readmission rate of COPD patients[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13(1): 3077-3083.
24 Jafarinejad H, Moghoofei M, Mostafaei S, et al. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis[J]. Microb Pathog, 2017, 113(1): 190-196.
25 Niespodziana K, Napora K, Cabauatan C, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections[J]. FASEB J, 2012, 26(3): 1001-1008.
26 Chen Y, Kumar RK, Thomas PS, et al. Th1/17-Biased inflammatory environment associated with COPD alters the response of airway epithelial cells to viral and bacterial stimuli[J]. Mediators Inflamm, 2019, 20(19): 7281462.

备注/Memo

备注/Memo:
通信作者: 孙 欣, Email: 452054828@qq.com
更新日期/Last Update: 2021-06-20